Nivalis Therapeutics Inc(NASDAQ:NVLS) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during After-hours on Aug 1, 2016. Earnings per share were $-0.55. Analysts had estimated an EPS of $-0.52.
Nivalis Therapeutics Inc (NVLS) made into the market gainers list on Mondays trading session with the shares advancing 7.36% or 0.37 points. Due to strong positive momentum, the stock ended at $5.4, which is also near the day’s high of $5.48. The stock began the session at $5.08 and the volume stood at 60,609 shares. The 52-week high of the shares is $20.43 and the 52 week low is $3.68. The company has a current market capitalization of $84 M and it has 1,55,03,149 shares in outstanding.
Several Insider Transactions has been reported to the SEC. On Jul 6, 2016, David Malcom Rodman (Exec Vice President and CMO) sold 5,950 shares at $4.66 per share price.Also, On Jun 17, 2016, Jon Congleton (CEO) purchased 5,000 shares at $3.87 per share price.On Dec 11, 2015, Robert E Conway (director) purchased 10,000 shares at $8.10 per share price, according to the Form-4 filing with the securities and exchange commission.
Nivalis Therapeutics Inc. is a United States-based clinical-stage pharmaceutical company. It is engaged in the discovery development and commercialization of product candidates for patients with cystic fibrosis. The Company has developed a portfolio of small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR) which is used to increase and prolong cystic fibrosis transmembrane conductance regulator (CFTR) activity and to decrease inflammation. Its drug candidate portfolio consists of various compounds for oral intravenous (IV) or inhaled administration. The Companys lead clinical candidate is N91115 which is an investigational small molecule that addresses a defect in CFTR resulting from mutations in the CFTR gene. N91115 is designed to stabilize CFTR inside the cell and at the cell surface. N91115 is a CFTR stabilizer that modulates CFTR activity.